Search results for " Mab"

Article Best Practices for Selecting a Top-Quality Cell Line
Once scaled up, the mAbs should be 5 to >10 g/L in the bioreactor. “This high level of productivity must also be maintained for more than 60 generations at the high-density and in the defined media co…

Article Biopharmaceutical Process Development: 2018 Lessons and 2019 Predictions
…ing of Biologic Drug Products  •  Tools and Solutions for Separation of Charged mAb Variants  •  Modern Manufacturing Key to More Effective Vaccines  •  Evaluation of Performance of a Dis…

Article Unifying Continuous Biomanufacturing Operations
Benchtop systems, then, could be sufficient for the commercial production of some mAbs. Integrated continuous bioprocessing is already regularly being achieved in small research labs, according to Bon…

Article Improvements in Protein A Chromatography
Alternative technologies like CEX capture or precipitation often provide lower purity and require more mAb-specific development. What future directions would you like to see in the development o…

Article A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
Reichert, MAbs. 7 (1), pp. 1–8 (2015). 2. S.D. Wijesuriya, R.L. Cotter, and A.H. Horwitz, Protein Expr. Purif. 92 (1), pp. 14–20 (2013). 3. D. Guo et al., Biotechnol. Bioeng. 107 (1), pp. 163–17…

Article Biopharma in 2015: A Year for Approvals and Innovations
First Hospira Biosimilar mAb Approved in West Europe, Randi Hernandez, Pharmaceutical Technology, Feb. 17, 2015. 3. Global & USA BioSimilar Market Analysis Report 2015-2021, Research and Markets, h…

Article Modular Manufacturing Platforms for Biologics
…n also be operational 12 months after project initiation, Almhem says, and there are several modular mAb facilities that are already in operation. In fact, modular systems are best for mAbs and are l…

Article Continuous Manufacturing: A Changing Processing Paradigm
Employing straight-through processing in mAb purification could significantly improve throughput with a much smaller manufacturing footprint, presenters of the aforementioned webinar conclude. Case st…

Article Purification strategies for antibody-derived entities: bispecifics and fragments
The safety and efficiency requirement of conventional mAb processes are key also for antibody variants. Here we present strategies for purifying bispecific antibodies and antibody fragments having the…

Article Selecting Chromatography Resins for Bispecific Antibody Purification
Targeting enhancement with two active antibody arms makes bispecific antibodies (bsAbs) highly attractive for the treatment of cancer and other diseases. Their purification can be more challen…

Previous PageNext Page